Drug Trial Radar · NCT05419492
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
113
Planned (sponsor's estimate)
Start
May 14, 2024
Primary completion
Jun 2028
Study completion Jun 2034
Sponsor
- Lead sponsor
- Encoded TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ENDEAVOR is a Phase 1/2, 2-part, multicenter study to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet syndrome aged ≥6 to \<36 months (Part 1A), aged ≥48 months to \<18 years (Part 1B), and aged ≥6 to \<48 months (Part 2). Part 1A follows an open-label, dose-escalation design, Part 1B follows an open-label design, and Part 2 is a randomized, double-blind, sham delayed-treatment control study.
Conditions
- Dravet Syndrome
Interventions
ETX101Drug
ETX101 is a non-replicating, recombinant adeno-associated viral vector serotype 9 (rAAV9) comprising a GABAergic regulatory element (reGABA) and an engineered transcription factor that increases transcription of the SCN1A gene (eTFSCN1A). ETX101 is intended as a one-time intracerebroventricular (ICV) administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change in monthly countable seizure frequency (MCSF) between the Pre-Dosing Seizure Period and the Post-Dosing Assessment Period.Time frame: Between the Pre-Dosing Seizure Period and the Post-Dosing Assessment Period (defined as Week 5 to Week 52).
Locations
14 sites in 3 countries. Site status is shown where the registry gives one.
UCSF Benioff Children's Hospitals
San Francisco, California · Recruiting
Colorado Children's Hospital
Aurora, Colorado · Recruiting
Nicklaus Children's Hospital
Miami, Florida · Recruiting
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois · Recruiting
Mott Children's Hospital
Ann Arbor, Michigan · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
NYU Langone Health
New York, New York · Not yet recruiting
Duke Children's Hospital & Health Center
Durham, North Carolina · Recruiting
Nationwide Children's Hospital
Columbus, Ohio · Recruiting
Oregon Health and Science University (OHSU)
Portland, Oregon · Recruiting
Cook Children's Medical Center
Fort Worth, Texas · Recruiting
The Royal Children's Hospital
Melbourne, Australia · Recruiting
Queen Elizabeth Hospital
Glasgow, United Kingdom · Recruiting
Great Ormond Street Hospital
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.